Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 89 articles:
HTML format
Text format



Single Articles


    March 2017
  1. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
    Clin Cancer Res. 2017 Mar 16. doi: 10.1158/1078-0432.CCR-16-1946.
    PubMed     Text format     Abstract available


    February 2017
  2. LAKSHMANAN I, Salfity S, Seshacharyulu P, Rachagani S, et al
    MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.2530.2016.
    PubMed     Text format     Abstract available


  3. VAN DER WEKKEN A, Pelgrim R, 't Hart N, Werner N, et al
    Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer.
    Clin Cancer Res. 2017 Feb 9. pii: clincanres.1631.2016.
    PubMed     Text format     Abstract available


    January 2017
  4. BONANNO L, De Paoli A, Zulato E, Esposito G, et al
    LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab.
    Clin Cancer Res. 2017 Jan 24. pii: clincanres.2410.2016.
    PubMed     Text format     Abstract available


  5. RATCLIFFE MJ, Sharpe A, Midha A, Barker C, et al
    Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2375.2016.
    PubMed     Text format     Abstract available


    December 2016
  6. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    GENOMIC PROFILING OF PATIENT-DERIVED XENOGRAFTS FOR LUNG CANCER IDENTIFIES B2M INACTIVATION IMPAIRING IMMUNORECOGNITION.
    Clin Cancer Res. 2016 Dec 21. pii: clincanres.1946.2016.
    PubMed     Text format     Abstract available


  7. TANIMOTO A, Takeuchi S, Arai S, Fukuda K, et al
    Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib-resistance in EGFR-mutant lung cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2271.2016.
    PubMed     Text format     Abstract available


  8. XUE Y, Lito P
    Predicting MEK inhibitor response in lung cancer: a proper signature is required.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.2576.2016.
    PubMed     Text format     Abstract available


  9. KHOZIN S, Weinstock C, Blumenthal GM, Cheng J, et al
    Osimertinib for the Treatment of Metastatic Epidermal Growth Factor T970M Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1773.2016.
    PubMed     Text format     Abstract available


    November 2016
  10. LIU G, Cuffe S, Liang S, Azad AK, et al
    BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1640.2016.
    PubMed     Text format     Abstract available


  11. SKOULIDIS F, Papadimitrakopoulou VA
    Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-small Cell Lung Cancer.
    Clin Cancer Res. 2016 Nov 7. pii: clincanres.2815.2015.
    PubMed     Text format     Abstract available


  12. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


  13. SKOULIDIS F, Papadimitrakopoulou VA
    Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.
    Clin Cancer Res. 2016;22:5177-5182.
    PubMed     Text format     Abstract available


    October 2016
  14. HULBERT A, Jusue Torres I, Stark A, Chen C, et al
    Early Detection of Lung Cancer using DNA Promoter Hypermethylation in Plasma and Sputum.
    Clin Cancer Res. 2016 Oct 11. pii: clincanres.1371.2016.
    PubMed     Text format     Abstract available


  15. RAMALINGAM SS, Blais N, Mazieres J, Reck M, et al
    Randomized, Placebo-Controlled, Phase 2 Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.3069.2016.
    PubMed     Text format     Abstract available


    September 2016
  16. GEORGE J, Saito M, Tsuta K, Iwakawa R, et al
    Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.1069.2016.
    PubMed     Text format     Abstract available


  17. THOMPSON JC, Yee SS, Troxel AB, Savitch SL, et al
    Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1231.2016.
    PubMed     Text format     Abstract available


  18. ZHOU W, Xu J, Li H, Xu M, et al
    Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage.
    Clin Cancer Res. 2016 Sep 2. pii: clincanres.1585.2016.
    PubMed     Text format     Abstract available


    August 2016
  19. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.3071.2015.
    PubMed     Text format     Abstract available


  20. MECKLENBURG I, Sienel W, Schmid S, Passlick B, et al
    A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung cancer.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.0557.2016.
    PubMed     Text format     Abstract available


    July 2016
  21. GETTINGER S, Politi K
    PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause?
    Clin Cancer Res. 2016 Jul 28. pii: clincanres.1401.2016.
    PubMed     Text format     Abstract available


  22. LOK BH, Gardner EE, Schneeberger VE, Ni A, et al
    PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.1040.2016.
    PubMed     Text format     Abstract available


  23. SCHALPER KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, et al
    Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0150.2016.
    PubMed     Text format     Abstract available


  24. LARKINS E, Blumenthal GM, Chen H, He K, et al
    FDA Approval: Alectinib for the Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
    Clin Cancer Res. 2016 Jul 13. pii: clincanres.1293.2016.
    PubMed     Text format     Abstract available


  25. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
    Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.1601.2015.
    PubMed     Text format     Abstract available


    June 2016
  26. WANG Y, Liu H, Diao L, Potter A, et al
    Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2190.2015.
    PubMed     Text format     Abstract available


  27. GIRARD L, Rodriguez-Canales J, Behrens C, Thompson DM, et al
    An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 28. pii: clincanres.2900.2015.
    PubMed     Text format     Abstract available


  28. YANAGITA M, Redig AJ, Paweletz CP, Dahlberg SE, et al
    A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016.
    PubMed     Text format     Abstract available


  29. WANG E, Nickens DJ, Bello A, Khosravan R, et al
    Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016.
    PubMed     Text format     Abstract available


  30. HAMILTON DH, Matthews Griner L, Keller JM, Hu X, et al
    Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3059.2015.
    PubMed     Text format     Abstract available


  31. GAPONOVA AV, Nikonova A, Deneka AY, Kopp MC, et al
    A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC).
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.3068.2015.
    PubMed     Text format     Abstract available


  32. SIVA S, Lobachevsky PN, MacManus M, Kron T, et al
    Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues.
    Clin Cancer Res. 2016 Jun 3. pii: clincanres.0138.2016.
    PubMed     Text format     Abstract available


  33. PARRA ER, Behrens C, Rodriguez-Canales J, Lin HY, et al
    Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.2443.2015.
    PubMed     Text format     Abstract available


  34. MORGENSZTERN D, Herbst RS
    Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.2998.2016.
    PubMed     Text format     Abstract available


    May 2016
  35. GAINOR JF, Shaw AT, Sequist LV, Fu X, et al
    EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis.
    Clin Cancer Res. 2016 May 25. pii: clincanres.3101.2015.
    PubMed     Text format     Abstract available


  36. TANG KJ, Constanzo J, Venkateswaran N, Melegari M, et al
    Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
    Clin Cancer Res. 2016 May 24. pii: clincanres.2603.2015.
    PubMed     Text format     Abstract available


    April 2016
  37. NILSSON MB, Giri U, Gudikote J, Tang X, et al
    KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
    Clin Cancer Res. 2016;22:1940-50.
    PubMed     Text format     Abstract available


  38. SHARMA A, Bender S, Zimmermann M, Riesterer O, et al
    Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2449.2015.
    PubMed     Text format     Abstract available


  39. DATAR I, Schalper KA
    Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.0336.2016.
    PubMed     Text format     Abstract available


  40. CORTOT AB, Moro-Sibilot D, Cadranel J
    Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter.
    Clin Cancer Res. 2016;22:1827.
    PubMed     Text format    


    March 2016
  41. DRILON A
    MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
    Clin Cancer Res. 2016 Mar 23. pii: clincanres.0229.2016.
    PubMed     Text format     Abstract available


  42. KAZANDJIAN D, Blumenthal GM, Yuan W, He K, et al
    FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2016;22:1307-12.
    PubMed     Text format     Abstract available


    February 2016
  43. RODRIGUEZ PC, Popa X, Martinez O, Mendoza S, et al
    A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer Patients.
    Clin Cancer Res. 2016 Feb 29. pii: clincanres.0855.2015.
    PubMed     Text format     Abstract available


  44. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Clin Cancer Res. 2016;22:923-34.
    PubMed     Text format     Abstract available


  45. REDIG AJ, Capelletti M, Dahlberg SE, Sholl LM, et al
    Clinical and molecular characteristics of NF1 mutant lung cancer.
    Clin Cancer Res. 2016 Feb 9. pii: clincanres.2377.2015.
    PubMed     Text format     Abstract available


  46. TONG JH, Yeung SF, Chan AW, Chung LY, et al
    MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-small Cell Lung Carcinoma with poor prognosis.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.2061.2015.
    PubMed     Text format     Abstract available


  47. DIAZ-LAGARES A, Mendez-Gonzalez J, Hervas D, Saigi M, et al
    A novel epigenetic signature for early diagnosis in lung cancer.
    Clin Cancer Res. 2016 Feb 3. pii: clincanres.2346.2015.
    PubMed     Text format     Abstract available


    January 2016
  48. TERASHIMA M, Togashi Y, Sato K, Mizuuchi H, et al
    Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2.
    Clin Cancer Res. 2016 Jan 29. pii: clincanres.2093.2015.
    PubMed     Text format     Abstract available


  49. GREEN H, Hasmats J, Kupershmidt I, Edsgard D, et al
    Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
    Clin Cancer Res. 2016;22:366-73.
    PubMed     Text format     Abstract available


  50. PIRAZZOLI V, Ayeni D, Meador CB, Sanganahalli BG, et al
    Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma.
    Clin Cancer Res. 2016;22:426-35.
    PubMed     Text format     Abstract available


  51. TAO Z, Le Blanc JM, Wang C, Zhan T, et al
    Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Clin Cancer Res. 2016;22:122-33.
    PubMed     Text format     Abstract available


    December 2015
  52. DRILON A, Somwar R, Wagner JP, Vellore NA, et al
    A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.2013.2015.
    PubMed     Text format     Abstract available


  53. GOVINDAN R, Mandrekar SJ, Gerber DE, Oxnard GR, et al
    ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015;21:5439-5444.
    PubMed     Text format     Abstract available


  54. TSUI DW, Berger MF
    Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.2514.2015.
    PubMed     Text format     Abstract available


  55. BELL EH, Chakraborty AR, Mo X, Liu Z, et al
    SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.1468.2015.
    PubMed     Text format     Abstract available


  56. MANSFIELD AS, Murphy SJ, Peikert T, Yi ES, et al
    Heterogeneity of programmed cell death-ligand 1 expression in multifocal lung cancer.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.2246.2015.
    PubMed     Text format     Abstract available


  57. GORGES TM, Penkalla N, Schalk T, Joosse S, et al
    Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.1416.2015.
    PubMed     Text format     Abstract available


  58. LEE JY, Sun JM, Lim SH, Kim H, et al
    A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.1653.2015.
    PubMed     Text format     Abstract available


  59. LI J, Ye C, Mansmann UR
    Comparing patient-derived xenograft and computational response prediction for targeted therapy in patients of early-stage large cell lung cancer.
    Clin Cancer Res. 2015 Dec 4. pii: clincanres.2401.2015.
    PubMed     Text format     Abstract available


  60. IAFRATE AJ
    CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors.
    Clin Cancer Res. 2015;21:5185-7.
    PubMed     Text format     Abstract available


    November 2015
  61. FERRAROTTO R, Goonatilake R, Yoo SY, Tong P, et al
    Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015 Nov 23. pii: clincanres.2890.2014.
    PubMed     Text format     Abstract available


    October 2015
  62. PAWELETZ CP, Sacher A, Raymond CK, Alden RS, et al
    Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients.
    Clin Cancer Res. 2015 Oct 12. pii: clincanres.1627.2015.
    PubMed     Text format     Abstract available


    August 2015
  63. IWAMOTO Y, Mitsudomi T, Sakai K, Yamanaka T, et al
    Randomized phase II study of adjuvant chemotherapy with long-term S-1 versus cisplatin+S-1 in completely resected stage II-IIIA non-small cell lung cancer.
    Clin Cancer Res. 2015 Aug 7. pii: clincanres.3160.2014.
    PubMed     Text format     Abstract available



  64. Correction: Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015;21:3571.
    PubMed     Text format    


    July 2015
  65. CASCONE T, Heymach JV
    Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
    Clin Cancer Res. 2015 Jul 31. pii: clincanres.1180.2015.
    PubMed     Text format     Abstract available


  66. DE ROSA V, Iommelli F, Monti M, Fonti R, et al
    Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer.
    Clin Cancer Res. 2015 Jul 27. pii: clincanres.0375.2015.
    PubMed     Text format     Abstract available


  67. KOBAYASHI Y, Togashi Y, Yatabe Y, Mizuuchi H, et al
    EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib and neratinib as compared with first or third generation TKIs.
    Clin Cancer Res. 2015 Jul 23. pii: clincanres.1046.2015.
    PubMed     Text format     Abstract available


  68. AYENI D, Politi K, Goldberg SB
    Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
    Clin Cancer Res. 2015 Jul 13. pii: clincanres.1211.2015.
    PubMed     Text format     Abstract available


  69. WEI R, Cao L, Pu H, Wang HW, et al
    TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015 Jul 6. pii: clincanres.0009.2015.
    PubMed     Text format     Abstract available


    June 2015
  70. DELLA CORTE CM, Bellevicine C, Vicidomini G, Vitagliano D, et al
    SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer.
    Clin Cancer Res. 2015 Jun 29. pii: clincanres.3319.2014.
    PubMed     Text format     Abstract available


  71. LARA PN JR, Longmate J, Mack PC, Kelly K, et al
    Phase II Study of the AKT inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed on Erlotinib.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.3281.2014.
    PubMed     Text format     Abstract available


  72. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


  73. CESCON DW, She D, Sakashita S, Zhu CQ, et al
    NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
    Clin Cancer Res. 2015;21:2499-505.
    PubMed     Text format     Abstract available


  74. CHOI S, Kim HR, Sung CO, Kim J, et al
    Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.
    Clin Cancer Res. 2015;21:2613-23.
    PubMed     Text format     Abstract available


  75. COLLISSON EA
    RB and Prognosis in Resected Lung Adenocarcinoma.
    Clin Cancer Res. 2015;21:2418-20.
    PubMed     Text format     Abstract available


    May 2015
  76. OTA K, Azuma K, Kawahara A, Hattori S, et al
    Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2015 May 27. pii: clincanres.0016.2015.
    PubMed     Text format     Abstract available



  77. Correction: ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer.
    Clin Cancer Res. 2015;21:2412.
    PubMed     Text format    


  78. SORIA JC, Marabelle A, Brahmer JR, Gettinger S, et al
    Immune checkpoint modulation for non-small cell lung cancer.
    Clin Cancer Res. 2015;21:2256-62.
    PubMed     Text format     Abstract available


  79. PIETANZA MC, Byers LA, Minna JD, Rudin CM, et al
    Small cell lung cancer: will recent progress lead to improved outcomes?
    Clin Cancer Res. 2015;21:2244-55.
    PubMed     Text format     Abstract available


  80. GANDARA DR, Hammerman PS, Sos ML, Lara PN Jr, et al
    Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
    Clin Cancer Res. 2015;21:2236-43.
    PubMed     Text format     Abstract available


  81. KATAYAMA R, Lovly CM, Shaw AT
    Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Clin Cancer Res. 2015;21:2227-35.
    PubMed     Text format     Abstract available


  82. RIELY GJ, Yu HA
    EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.
    Clin Cancer Res. 2015;21:2221-6.
    PubMed     Text format     Abstract available


  83. POLITI K, Herbst RS
    Lung cancer in the era of precision medicine.
    Clin Cancer Res. 2015;21:2213-20.
    PubMed     Text format     Abstract available


  84. BATES SE
    Quit early, quit often.
    Clin Cancer Res. 2015;21:2212.
    PubMed     Text format    


    April 2015
  85. ARCILA ME, Drilon A, Sylvester BE, Lovly CM, et al
    MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
    Clin Cancer Res. 2015;21:1935-43.
    PubMed     Text format     Abstract available


    March 2015
  86. STARMANS MH, Pintilie M, Chan-Seng-Yue M, Moon NC, et al
    Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
    Clin Cancer Res. 2015;21:1477-86.
    PubMed     Text format     Abstract available


    February 2015
  87. YOSHIDA T, Ishii G, Goto K, Neri S, et al
    Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Clin Cancer Res. 2015;21:642-51.
    PubMed     Text format     Abstract available


    January 2015
  88. LIN YC, Lin YC, Shih JY, Huang WJ, et al
    DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Clin Cancer Res. 2015;21:428-38.
    PubMed     Text format     Abstract available


  89. KATAYAMA R, Kobayashi Y, Friboulet L, Lockerman EL, et al
    Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Clin Cancer Res. 2015;21:166-74.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: